Caseware UK (AP4) 2025.0.111 2025.0.111 2025-12-312025-12-312025-01-01falseprovision of software development and data managment within the pharmaceutical and healthcare industry55truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 07778793 2025-01-01 2025-12-31 07778793 2024-01-01 2024-12-31 07778793 2025-12-31 07778793 2024-12-31 07778793 c:Director1 2025-01-01 2025-12-31 07778793 d:ComputerEquipment 2025-01-01 2025-12-31 07778793 d:ComputerEquipment 2025-12-31 07778793 d:ComputerEquipment 2024-12-31 07778793 d:ComputerEquipment d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 07778793 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-12-31 07778793 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-12-31 07778793 d:CurrentFinancialInstruments 2025-12-31 07778793 d:CurrentFinancialInstruments 2024-12-31 07778793 d:Non-currentFinancialInstruments 2025-12-31 07778793 d:Non-currentFinancialInstruments 2024-12-31 07778793 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-31 07778793 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 07778793 d:Non-currentFinancialInstruments d:AfterOneYear 2025-12-31 07778793 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 07778793 d:ShareCapital 2025-12-31 07778793 d:ShareCapital 2024-12-31 07778793 d:SharePremium 2025-01-01 2025-12-31 07778793 d:SharePremium 2025-12-31 07778793 d:SharePremium 2024-12-31 07778793 d:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31 07778793 d:RetainedEarningsAccumulatedLosses 2025-12-31 07778793 d:RetainedEarningsAccumulatedLosses 2024-12-31 07778793 c:OrdinaryShareClass1 2025-01-01 2025-12-31 07778793 c:OrdinaryShareClass1 2025-12-31 07778793 c:OrdinaryShareClass2 2025-01-01 2025-12-31 07778793 c:OrdinaryShareClass2 2025-12-31 07778793 c:OrdinaryShareClass3 2025-01-01 2025-12-31 07778793 c:OrdinaryShareClass3 2025-12-31 07778793 c:FRS102 2025-01-01 2025-12-31 07778793 c:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 07778793 c:FullAccounts 2025-01-01 2025-12-31 07778793 c:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 07778793 d:Subsidiary1 2025-01-01 2025-12-31 07778793 d:Subsidiary1 1 2025-01-01 2025-12-31 07778793 d:Subsidiary2 2025-01-01 2025-12-31 07778793 d:Subsidiary2 1 2025-01-01 2025-12-31 07778793 d:Subsidiary3 2025-01-01 2025-12-31 07778793 d:Subsidiary3 1 2025-01-01 2025-12-31 07778793 6 2025-01-01 2025-12-31 07778793 15 2025-01-01 2025-12-31 07778793 17 2025-01-01 2025-12-31 07778793 19 2025-01-01 2025-12-31 07778793 20 2025-01-01 2025-12-31 07778793 d:DevelopmentCostsCapitalisedDevelopmentExpenditure d:OwnedIntangibleAssets 2025-01-01 2025-12-31 07778793 e:PoundSterling 2025-01-01 2025-12-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 07778793









GENESTACK LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2025

 
GENESTACK LIMITED
REGISTERED NUMBER: 07778793

BALANCE SHEET
AS AT 31 DECEMBER 2025

2025
2024
Note
£
£

FIXED ASSETS
  

Intangible assets
 4 
1,111,302
2,588,554

Tangible assets
 5 
19,047
14,883

Investments
 6 
173
173

  
1,130,522
2,603,610

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 7 
1,235,147
952,529

Cash at bank and in hand
  
62,709
7,980

  
1,297,856
960,509

Creditors: amounts falling due within one year
 8 
(1,804,221)
(1,292,759)

NET CURRENT LIABILITIES
  
 
 
(506,365)
 
 
(332,250)

TOTAL ASSETS LESS CURRENT LIABILITIES
  
624,157
2,271,360

Creditors: amounts falling due after more than one year
 9 
(6,712)
(88,205)

NET ASSETS
  
617,445
2,183,155


CAPITAL AND RESERVES
  

Called up share capital 
 10 
1,002
1,002

Share premium account
 11 
8,021,253
8,021,253

Profit and loss account
 11 
(7,404,810)
(5,839,100)

  
617,445
2,183,155


Page 1

 
GENESTACK LIMITED
REGISTERED NUMBER: 07778793
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Dr M Kapushesky
Director

Date: 4 September 2026

The notes on pages 3 to 13 form part of these financial statements.

Page 2

 
GENESTACK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.


GENERAL INFORMATION

Genestack Limited (the 'Company') is a private company limited by shares and incorporated in England and Wales. Its registered office address is Salisbury House, Station Road, Cambridge, CB1 2LA.

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

GOING CONCERN

The financial statements have been prepared on a going concern basis, which assumes that the Company will continue trading for the foreseeable future. The Company has a history of operating losses and has been financed to date by corporate shareholder loans; this lender has indicated their continuing support. Given this, along with the development progress achieved, the directors are of the opinion that sufficient funding will be available for the Company to meet its liabilities as they fall due.

 
2.3

EXEMPTION FROM PREPARING CONSOLIDATED FINANCIAL STATEMENTS

The Company, and the Group headed by it, qualify as small as set out in section 383 of the Companies Act 2006 and the parent and Group are considered eligible for the exemption to prepare consolidated accounts.

 
2.4

TURNOVER

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:

Rendering of services

Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of turnover can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Turnover from licence sales is recognised in the Profit and Loss Account over the period that the licence covers. 

Page 3

 
GENESTACK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.5

INTANGIBLE ASSETS

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

Development expenditure is amortised over 5 years.

 
2.6

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Computer equipment
-
33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

VALUATION OF INVESTMENTS

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.8

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. 

 
2.9

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 4

 
GENESTACK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.10

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.11

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

 
2.12

OPERATING LEASES

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

 
2.13

PENSIONS

DEFINED CONTRIBUTION PENSION PLAN

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in other creditors as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 5

 
GENESTACK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.14

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.15

RESEARCH AND DEVELOPMENT

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.16

FINANCE COSTS

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

Page 6

 
GENESTACK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.17

SHARE-BASED PAYMENTS

The cost and corresponding increase in equity in respect of equity-settled share-based payment transactions with employees are measured by reference to the fair value of equity instruments issued at the date of grant.  Amounts are expensed on a straight-line basis over the vesting period based on the estimate of shares that will eventually vest and adjusted for the effect of non-market-based vesting conditions.  The cost and fair value of the liability incurred in respect of cash-settled transactions is measured using an appropriate option pricing model with changes in fair value recognised in profit or loss for the period.

 
2.18

FINANCIAL INSTRUMENTS

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Balance Sheet when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

Basic financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Page 7

 
GENESTACK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.ACCOUNTING POLICIES (CONTINUED)


2.18
FINANCIAL INSTRUMENTS (CONTINUED)

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

Derecognition of financial assets

Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.


3.


EMPLOYEES

The average monthly number of employees, including directors, during the year was 5 (2024 - 5).

Page 8

 
GENESTACK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

4.


INTANGIBLE ASSETS




Development expenditure

£



COST


At 1 January 2025
12,837,333



At 31 December 2025

12,837,333



AMORTISATION


At 1 January 2025
10,248,779


Charge for the year on owned assets
1,477,252



At 31 December 2025

11,726,031



NET BOOK VALUE



At 31 December 2025
1,111,302



At 31 December 2024
2,588,554

The useful economic life of previously capitalised development expenditure was reassessed and extended from the end of 2025 to the end of 2027. This change has been accounted for prospectively as a change in accounting estimate. The effect of the change was to reduce the amortisation charge for the year by £1,111,304.


Page 9

 
GENESTACK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

5.


TANGIBLE FIXED ASSETS


Computer equipment

£



COST 


At 1 January 2025
27,250


Additions
11,015


Disposals
(4,150)



At 31 December 2025

34,115



DEPRECIATION


At 1 January 2025
12,367


Charge for the year on owned assets
6,344


Disposals
(3,643)



At 31 December 2025

15,068



NET BOOK VALUE



At 31 December 2025
19,047



At 31 December 2024
14,883

Page 10

 
GENESTACK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

6.


FIXED ASSET INVESTMENTS





Investments in subsidiary companies

£



COST


At 1 January 2025
173



At 31 December 2025
173





SUBSIDIARY UNDERTAKINGS


The following were subsidiary undertakings of the Company:

Name

Class of shares

Holding

Genestack Services Limited
Ordinary
100%
Genestack d.o.o. Beograd
Ordinary
100%
Genestack USA, Inc.
Common stock
100%


7.


DEBTORS

2025
2024
£
£

Trade debtors
765,572
614,828

Other debtors
147,019
130,088

Prepayments and accrued income
250,427
27,632

Tax recoverable
72,129
179,981

1,235,147
952,529


Page 11

 
GENESTACK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

8.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2025
2024
£
£

Trade creditors
34,754
57,014

Amounts owed to group undertakings
167,821
135,973

Other taxation and social security
112,160
119,584

Other creditors
30,138
20,568

Accruals and deferred income
1,459,348
959,620

1,804,221
1,292,759


Other creditors include contributions of £NIL (2024 - £NIL) payable to the Company's defined contribution pension scheme at the balance sheet date.


9.


CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

2025
2024
£
£

Accruals and deferred income
6,712
88,205



10.


SHARE CAPITAL

2025
2024
£
£
ALLOTTED, CALLED UP AND FULLY PAID



99,101 Ordinary A shares of £0.0100 each
991
991
1,001 Ordinary B shares of £0.0100 each
10
10
8,116 Preference shares of £0.0001 each
1
1

1,002

1,002

Share rights

Ordinary A shares carry one vote per share and rank equally for dividends and capital distributions, including on a winding up. 

Ordinary B shares rank equally with Ordinary A shares except that they do not carry voting rights or rights to attend, speak at or receive notice of general meetings. Transfers of Ordinary B shares require the prior written consent of the majority shareholder.

Preference shareholders are entitled to receive notice of, attend and speak at general meetings but do not have voting rights. Holders are entitled to a preferential dividend out of available distributable profits, apportioned according to the number of preference shares held.


Page 12

 
GENESTACK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

11.


RESERVES

Share premium account

Includes any premiums received on issue of share capital. Any transaction costs associated with the issuing of shares are deducted from share premium.

Profit and loss account

Includes all current and prior year retained profits and losses.


12.


SHARE-BASED PAYMENTS

The Company has granted options over Ordinary B shares to certain key employees.

As at the balance sheet date, a total of 7,582 share options had been granted, of which 4,777 had vested.

The directors have assessed the fair value of the options granted and concluded that any share-based payment charge arising is not material. Accordingly, no share-based payment expense has been recognised in the current or prior period.

 
Page 13